KLK3 and prostate carcinoma: Some studies suggest that patients in the PSA gray zone may exhibit more complex clinical features, and therefore, the development of new biomarkers, especially miRNAs, could help improve the diagnostic accuracy in the PSA gray zone and provide more sensitive and specific tools for early prostate cancer screening7,8.